Sermorelin was originally approved by the FDA in 1997 for treating growth hormone deficiency in children, but was discontinued in 2008 due to manufacturing issues, not safety concerns
Six clinical trials enrolling ~900 participants demonstrated excellent safety but the pivotal Phase IIb trial failed to show clinically meaningful weight loss, leading to development termination in 2007
However, avoid administering it with strong acid or vitamin C formulations in the same session, as peptides can degrade at low pH
R., Brocato, L., Manzato, E., Berchio, A., Massarenti, P., Settanni, F., Della, Casa L., Bergamini, S., and Iannone, A
Women under 40 Premenopausal women on GLP-1 medications face hair loss primarily from telogen effluvium and nutritional depletion
KLOW (BPC-157 10mg + GHK-Cu 50mg + TB-500 10mg + KPV 10mg) 80mg Research-grade KLOW Blend, a four-peptide complex combining BPC-157 (10mg), GHK-Cu (50mg), TB-500 (10mg), and KPV (10mg) studied for tissue repair, extracellular matrix remodeling, skin regeneration, and anti-inflammatory signaling pathways
